Skip to content
Menu

Alpha Buying: 3 Beaten-Down Biotech Stocks Backed by a Specialist Investor

Tim Melvin 3 weeks ago

Opinion

There are parts of the stock market where I am comfortable doing the research myself.Give me a community bank’s balance sheet, loan portfolio, and deposit information, and I can usually figure out whether the shares

There are parts of the stock market where I am comfortable doing the research myself.

Give me a community bank’s balance sheet, loan portfolio, and deposit information, and I can usually figure out whether the shares deserve a closer look.

Hand me the clinical results for an experimental antibody, and I am going to need some help.

I suspect most of you would, too.

Reading a company’s investor presentation does not qualify us to decide whether its drug works better than the competition.

The presentation is supposed to make us enthusiastic. They generally leave out the slide that says, “There is a decent chance this all goes badly.”

That creates a problem because biotechnology is one of the few places where a small company can develop something worth many times its current stock market value.

Fivefold and tenfold gains are possible. Occasionally, the returns are much larger.

The attraction is easy to understand.

Finding the right companies is the hard part.

That is where following experienced investors can help.

Matthew Perry, who runs Coastlands Capital in San Francisco, recently disclosed substantial stakes in three small biotechnology companies:

Coastlands reported ownership of 9.72%, 5.69%, and 6.67%, respectively.

I think those filings are worth our time.

Following an Investor Who Knows Biotechnology

Matthew Perry has spent decades evaluating biotechnology companies, financing their research, and working with their management teams.

He joined Biotechnology Value Fund Partners in December 1996 and eventually became its president and a portfolio manager.

He left in 2024 and launched Coastlands Capital in 2025.

Perry has also served on the boards of XOMA and CTI BioPharma, which was sold in 2023.

That is the kind of experience I want to see when we are examining companies whose futures depend on experimental medicines.

Coastlands reported approximately $785 million in regulatory assets under management at the end of 2025.

The firm describes its investment approach as fundamental and value-oriented, with a focus on small- and microcap biotechnology companies.

It also invests through warrants, preferred equity, and negotiated financings.

The value emphasis appeals to me.

Even a promising medicine can be a poor investment if you pay too much for it.

And clinical-stage biotechnology requires a different kind of research from most of the businesses we discuss.

These companies are testing experimental treatments in people.

Many have little revenue and no approved products.

We are trying to determine what a medicine could eventually earn, how much it will cost to get there, and whether it will succeed at all.

The payoff can be enormous.

But the risks are equally real.

Why Specialist Ownership Matters

Verdad’s biotechnology research offers a useful example of what can happen when a small company develops a successful treatment.

Pharmacyclics traded near $1 during the financial crisis.

Its cancer treatment, Imbruvica, eventually helped lead to AbbVie’s $21 billion acquisition in 2015, with Pharmacyclics shares reaching $261.25.

Everybody would like to own something like that.

Few of us can independently sort through the science well enough to identify the next one.

Biotechnology specialists have research teams, access to physicians and scientists, and years of experience interpreting clinical results.

Many have M.D.s or Ph.D.s.

They understand why a clinical trial enrolled particular patients, whether the dose makes sense, and how a safety finding might affect a drug’s future.

Those degrees do not guarantee investment success.

Experienced investors without them can also develop deep expertise.

But most of us are not going to reproduce that research between breakfast and lunch.

We can, however, pay attention to what those investors own.

The Research Behind Following Biotech Specialists

Verdad tested this approach in its white paper, Biotech Investing.

From September 2013 through October 2025, the group of biotechnology stocks with the highest concentration of specialist ownership returned approximately 20% annually.

The group with the lowest concentration returned approximately negative 2% annually.

The analysis excluded companies held by no funds.

That is a substantial difference.

Verdad also found that the strongest signals appeared when several biotechnology specialists owned the same company.

Their holdings remained informative even with the delay associated with quarterly 13F reporting.

Of course, these are historical research results.

They are not returns that every investor should expect to earn by copying a specialist fund.

Still, the findings give us a useful way to narrow our search.

We can begin with companies attracting knowledgeable investors, then examine their valuations, cash positions, and upcoming clinical developments.

Perry’s three recent disclosures give us a place to start.

Finding other experienced specialists invested alongside him would make the ownership evidence even more compelling.

What the SEC Filings Actually Tell Us

The three ownership disclosures came through Schedule 13G filings.

A Schedule 13G tells the Securities and Exchange Commission that an eligible investor has beneficial ownership of more than 5% of a covered class of stock.

Beneficial ownership generally concerns voting or investment power over the shares.

Qualifying institutions, passive investors, and certain exempt investors can use this shorter alternative to Schedule 13D.

Coastlands’ filings report ownership without a purpose of changing or influencing control of these companies.

In other words, these are disclosed financial interests, not announced activist campaigns to replace management or force a sale.

We also need to be careful about interpreting the timing.

A filing date is not necessarily the date shares were purchased.

And a 13G does not reveal the investor’s complete purchase history or every financing term.

If a fund owns warrants or preferred securities, its investment may work differently from the common shares available to us.

Those distinctions matter.

But a substantial ownership position from an investor with Perry’s experience is still worth investigating.

Let’s look at the three companies.

1. iBio (IBIO): A New Approach to Obesity and Muscle Preservation

iBio is the first company that caught my attention.

Coastlands filed its ownership disclosure on October 14, reporting 6,247,738 common shares, representing 9.72% ownership.

The filing excludes certain warrants and pre-funded warrants because of ownership limitations.

That is a meaningful position in a small biotechnology company.

And iBio is working on a medical problem with considerable commercial potential.

The company develops antibody medicines using computational tools and an artificial intelligence-supported discovery platform.

Its pipeline focuses on obesity and related metabolic conditions.

The business idea is easier to understand than some of the scientific terminology.

Helping people lose weight is useful.

Helping them lose fat while preserving muscle could make treatment better.

The Potential of IBIO-600

iBio’s lead drug candidate, IBIO-600, targets myostatin, a protein involved in limiting muscle growth.

The company hopes the treatment can preserve muscle and improve body composition during weight loss.

That could eventually include use alongside GLP-1 medicines.

The first participant in its Phase 1 clinical trial was dosed in June.

iBio also has two additional programs:

  • IBIO-610: An antibody program targeting Activin E.
  • IBIO-800: A program targeting both myostatin and Activin A.

The company’s September presentation anticipated interim Phase 1 results for IBIO-600 in the first quarter of 2027.

Those results will be important.

There is an appealing medical idea here, but we still need human clinical data to determine whether the company can turn that idea into an effective treatment.

A Beaten-Down Share Price

iBio shares closed at approximately $0.707, or 71 cents, on October 26.

They traded around $1.20 in mid-September.

Anyone expecting Coastlands’ ownership to put an immediate floor under the stock has been disappointed.

That is a useful reminder.

Even experienced investors cannot prevent a speculative biotechnology stock from declining.

And a low share price, by itself, tells us very little about whether a company is undervalued.

What interests me is the combination of a medical problem worth solving, human clinical data on the way, and an experienced investor with a substantial stake.

If the science works, the opportunity could be significant.

If it does not, the low share price will provide little comfort.

IBIO belongs on the research list because of its pipeline and specialist ownership, not simply because the shares have fallen.

2. Kalaris Therapeutics (KLRS): A Retinal Treatment With an Interesting Cash Valuation

Kalaris Therapeutics is working on a problem that many families know all too well.

Deteriorating eyesight.

Coastlands filed its ownership disclosure on October 26, reporting 1,355,119 shares, or 5.69% ownership.

Kalaris develops treatments for retinal diseases.

Its lead drug candidate, TH103, targets wet age-related macular degeneration, with potential applications in other retinal conditions.

The company was founded by Dr. Napoleone Ferrara, whose research helped establish the anti-VEGF approach used to treat these diseases.

That scientific background is worth paying attention to.

Could TH103 Make Eye Treatments Last Longer?

TH103 is designed to inhibit VEGF activity while remaining in the eye longer.

The goal is better disease control and a longer-lasting treatment.

That would be welcome news for patients who require repeated injections into the eye.

I doubt anyone needs much convincing about the appeal of making those appointments less frequent.

Kalaris is currently conducting a Phase 1b/2 clinical study.

The company expects preliminary results in the first half of 2027.

Those results should help investors evaluate whether TH103 can deliver on its intended benefits.

The company also has a financial position that deserves attention.

A Market Value Well Below Previously Reported Cash

In August, management said Kalaris held approximately $93.5 million in cash, cash equivalents, and marketable securities as of June 30.

The company expected that funding to support operations into the fourth quarter of 2027.

Now consider the share price.

KLRS closed at $1.80 on October 26, down approximately 37% from $2.85 on October 1.

With roughly 23.8 million shares outstanding, that puts the company’s equity market value near $43 million.

That is well below the cash and securities reported at the end of June.

The comparison gets my attention.

But we have to be careful.

Some of that cash has been spent since June.

There are also liabilities, continuing research expenses, and the cost of advancing clinical development.

The previously reported cash balance is not the same thing as cash available for immediate distribution to shareholders.

Still, the relationship between the market value and reported financial resources deserves investigation from anyone interested in biotechnology value investing.

We have a company pursuing an established treatment market, reported funding expected to carry it through an important clinical milestone, and a share price that suggests investors have very little patience left.

That is the sort of situation I want to examine when someone with Perry’s background owns a meaningful position.

KLRS combines a potentially valuable treatment opportunity with an unusually interesting comparison between its equity valuation and previously reported cash resources.

The clinical results and ongoing cash consumption will determine whether that apparent opportunity is real.

3. OnKure Therapeutics (OKUR): Precision Cancer Treatments With Funding Into 2029

The third company, OnKure Therapeutics, is developing precision medicines for cancer and vascular abnormalities.

Coastlands filed its ownership disclosure on October 7, reporting 2.7 million shares, representing 6.67% ownership.

The filing excludes certain pre-funded warrants subject to an ownership limitation.

OnKure’s research focuses on PI3K alpha, a protein whose mutated forms can drive disease.

The company’s goal is to attack those mutated forms while sparing the normal protein.

The hope is that greater selectivity will allow effective treatment with fewer unwanted effects.

That is an attractive scientific objective.

But, as with any experimental medicine, the clinical results will ultimately determine whether it works.

Two New Drug Candidates Lead the Pipeline

OnKure is now prioritizing two programs:

  • OKI-355: A candidate targeting vascular anomalies.
  • OKI-345: A candidate targeting breast cancer.

In August, management said it planned to submit applications to begin clinical testing for both candidates in the first half of 2027.

That gives us specific developments to monitor.

There is also an important distinction for anyone reviewing older research on the company.

Earlier discussions of OnKure focused heavily on another candidate, OKI-219.

The company has since said it does not plan to pursue further independent clinical development of that drug.

The newer candidates are where management is directing its efforts.

We need to evaluate the business based on the pipeline it is actually pursuing today, not the programs that dominated previous investor presentations.

A Substantial Cash Position

OnKure reported $176.4 million in cash, cash equivalents, and marketable securities as of June 30.

Management expected that funding to last into 2029.

That is an important consideration for a clinical-stage biotechnology company.

Drug development is expensive.

A company that can fund its research through important milestones may be in a better position than one forced to raise additional capital at an unfavorable share price.

Of course, a cash runway is an estimate.

Spending plans can change, and additional financing may eventually be necessary.

But the reported financial position gives OnKure resources to pursue its newer programs.

The stock closed at approximately $2.475, or $2.48, on October 26, up from $2.10 on October 16.

That is a welcome rebound.

But the investment will ultimately depend on the drugs and their results.

What interests me is that OnKure has money to pursue its newer pipeline and a specialist investor willing to own a substantial piece of the company.

OKUR is worth watching as its newer drug candidates move toward clinical testing.

The company’s ability to turn those programs into successful treatments will matter far more than the next short-term move in its share price.

Three Biotech Stocks, Three Different Opportunities

These companies are pursuing very different medical problems.

iBio (IBIO) is developing antibody treatments that could help preserve muscle during weight loss.

Its next important milestone is interim human clinical data for IBIO-600, expected in the first quarter of 2027.

Kalaris Therapeutics (KLRS) is developing a retinal treatment intended to provide longer-lasting disease control.

Its preliminary Phase 1b/2 results are expected in the first half of 2027, and its equity valuation relative to previously reported cash deserves further investigation.

OnKure Therapeutics (OKUR) is developing precision medicines for cancer and vascular abnormalities.

The company is concentrating on newer drug candidates, with applications to begin clinical testing planned for the first half of 2027.

What connects them is the involvement of Coastlands Capital.

Matthew Perry has spent decades evaluating biotechnology companies.

His firm has disclosed meaningful ownership positions in all three.

That does not mean every investment will succeed.

It does mean we have a reason to investigate these businesses more closely.

And that is the point of following specialist investors.

We are not outsourcing every investment decision.

We are using their disclosed holdings to identify companies that deserve additional research.

Keep the Positions Small and Let the Science Do the Talking

I would keep positions in companies like these small and spread the money around.

A disappointing clinical trial result can do more damage than a stop order can prevent.

Perry will have investments that fail, just like every other biotechnology investor.

Even the most experienced specialists cannot eliminate the risks involved in developing experimental medicines.

But I do not want to ignore a part of the market where successful treatments can produce extraordinary gains simply because I cannot personally evaluate every scientific detail.

Following experienced specialists gives us a sensible way to participate.

Verdad’s research supports using specialist ownership to refine the search.

And these three Coastlands filings have put specific companies on our list.

For iBio, I will be watching the human data on muscle preservation during weight loss.

For Kalaris, the next clinical results will help show whether TH103 can improve retinal treatment.

At OnKure, progress with the newer drug candidates will tell us whether the company’s change in direction is paying off.

Those developments will matter a great deal more than tomorrow morning’s market commentary.

Read at benzinga.com